A wonderful business — priced for growth it hasn't delivered.
A great company, but no margin of safety at this price. Worth watching, not worth buying here.
Price against fair value
Free cash flow — 5-year history ($B)
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
The read — lights & verdict
- OvervaluedFair value ~$66 vs $83 — trading 21% above what the math supports.
- Price assumes a modest step-upPriced for ~8%/yr vs a 5.8%/yr record — a stretch, not heroic.
- Revenue still growingUp 8.4% last year — demand isn't the problem.
- Cash flow compoundingFree cash flow up ~5.8%/yr — the engine is growing.
- Manageable net debtNet debt of $19B — about 3.5× annual free cash flow. Normal for a mature company.
How this was built. Every figure is computed from Medtronic plc's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY26 annual report and change only when a new one is filed. Price of $83.21 taken 2026-07-24 (founder-supplied CSV, July 2026) — it is not live and does not move during the day.